Preclinical evaluation of [¹¹C]CHDI-009R for quantification of mutant huntingtin aggregates.

ABSTRACT: Huntington's disease (HD) is a neurodegenerative disorder caused by an expanded trinucleotide repeat in the huntingtin gene (HTT) that subsequently leads to aggregation of the mutant huntingtin (mHTT) protein. Thus, lowering mHTT is a key therapeutic approach used by several candidate therapeutics currently under investigation. Visualization of the efficiency of these therapeutics through in vivo mHTT quantification rises in importance. For positron emission tomography (PET) imaging of mHTT aggregates, it is critical to characterize the in vivo kinetic profile of newly identified mHTT binders to assess their translational application. Here, we report the evaluation of [¹¹C]CHDI-009R, a PET imaging radioligand with higher affinity and selectivity for mHTT aggregates than previous

SUBMITTER: Zajicek F 

PROVIDER: S-EPMC12715049 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature